Orchid Chemicals & Pharmaceuticals on Monday said it has received US health regulator's approval to sell anti-epileptic levetiracetam tablets in the American market.
The company has received approval from USFDA for levetiracetam tablets in strength of 1,000 mg, it said.
Shares of Orchid Chemicals & Pharmaceuticals were trading at Rs 190.30 on BSE in late afternoon trade, up 0.58 per cent from its previous close.
Sun Pharma gets USFDA nod for epilepsy drug
Battle of the bourses: Will BSE rebound?
TCS Q1 net profit slips 4.5% to Rs 1,906 crore
Issues with USFDA to take long to resolve: Ranbaxy
BSE to launch SME exchange by year-end